Quidel Co. (NASDAQ:QDEL) Expected to Announce Earnings of $0.78 Per Share
Wall Street brokerages expect Quidel Co. (NASDAQ:QDEL) to report earnings of $0.78 per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Quidel’s earnings. The highest EPS estimate is $0.87 and the lowest is $0.74. Quidel reported earnings of $0.80 per share in the same quarter last year, which suggests a negative year over year growth rate of 2.5%. The firm is expected to report its next quarterly earnings results on Wednesday, February 12th.
On average, analysts expect that Quidel will report full-year earnings of $2.74 per share for the current financial year, with EPS estimates ranging from $2.70 to $2.84. For the next financial year, analysts anticipate that the firm will report earnings of $3.15 per share, with EPS estimates ranging from $2.89 to $3.57. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Quidel.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.06. Quidel had a return on equity of 22.48% and a net margin of 14.51%. The firm had revenue of $126.50 million for the quarter, compared to analyst estimates of $125.52 million. During the same period in the previous year, the company posted $0.59 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year.
QDEL traded up $2.41 on Friday, hitting $64.19. 162,200 shares of the stock traded hands, compared to its average volume of 207,601. Quidel has a 52 week low of $44.27 and a 52 week high of $70.31. The company has a current ratio of 1.46, a quick ratio of 0.97 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.49 billion, a PE ratio of 22.76 and a beta of 1.41. The business has a fifty day moving average price of $59.68 and a two-hundred day moving average price of $59.42.
In other news, Director Kenneth F. Buechler sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $68.86, for a total value of $275,440.00. Following the sale, the director now directly owns 54,433 shares in the company, valued at approximately $3,748,256.38. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Douglas C. Bryant sold 71,708 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $62.18, for a total value of $4,458,803.44. Following the completion of the sale, the chief executive officer now owns 326,692 shares in the company, valued at $20,313,708.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 118,361 shares of company stock worth $312,782,451. Corporate insiders own 14.10% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its holdings in shares of Quidel by 0.5% in the 2nd quarter. First Light Asset Management LLC now owns 54,943 shares of the company’s stock worth $3,259,000 after acquiring an additional 268 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Quidel by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,451,846 shares of the company’s stock worth $204,764,000 after acquiring an additional 250,095 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Quidel by 12.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 111,680 shares of the company’s stock worth $6,625,000 after acquiring an additional 12,785 shares in the last quarter. Pitcairn Co. boosted its holdings in shares of Quidel by 2.6% in the 2nd quarter. Pitcairn Co. now owns 7,214 shares of the company’s stock worth $428,000 after acquiring an additional 182 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Quidel by 7.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 25,692 shares of the company’s stock worth $1,524,000 after acquiring an additional 1,742 shares in the last quarter. Institutional investors own 89.39% of the company’s stock.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Article: What causes a stock to be most active?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.